Zylox-Tonbridge Medical Technology Co., Ltd. Class H (2190) Price & Analysis

Compare

1 Followers

2190 Stock Chart & Stats

HK$24.64

HK$0.06(0.55%)

At close: Jan 09 4:00 PM EST

HK$24.64

HK$0.06(0.55%)

Day’s Range― - ―

52-Week RangeHK$10.56 - HK$26.60

Previous CloseN/A

Volume305.57K

Average Volume (3M)525.30K

Market Cap

HK$7.83B

Enterprise ValueHK$5.09B

Total Cash (Recent Filing)HK$1.61B

Total Debt (Recent Filing)HK$83.12M

Price to Earnings (P/E)46.2

Beta0.62

Next Earnings

Mar 19, 2026

EPS EstimateN/A

Last Dividend Ex-Date

Jun 04, 2025

Dividend Yield0.46%

Share Statistics

EPS (TTM)0.40

Shares Outstanding322,400,760

10 Day Avg. Volume572,538

30 Day Avg. Volume525,305

Financial Highlights & Ratios

PEG Ratio-0.16

Price to Book (P/B)1.15

Price to Sales (P/S)4.57

P/FCF Ratio-207.21

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$28.62

Price Target Upside16.16% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)4.73

Revenue Forecast (FY)HK$8.27B

Bulls Say, Bears Say

Bulls Say

Financial PerformanceAdjusted net income surged by 68.1% year over year to Rmb131mn, reaching an adjusted net margin of 27.3%.

Global ExpansionZylox is actively establishing a localized commercial team globally, and as overseas sales scale expands, gross profit margin is expected to be similar to that of the China business level.

Market OpportunitiesVBP guidelines are becoming more lenient, allowing new entrants to participate at the average bidding price from the last round, which should benefit quality new domestic entrants like Zylox.

Bears Say

Expansion RisksManagement targets overseas sales to account for approximately 20-30% of the total by 2027, seeking to expedite expansion via mergers and acquisitions with a target sales scale of Rmb100mn+.

Investment RisksThe risk-reward update suggests favorable conditions for investment in Zylox-Tonbridge Medical Technology Co.

Market CompetitionProjected sales and net profit growth are strong, aligning with management guidance.

Zylox-Tonbridge Medical Technology Co., Ltd. Class H News

Zylox-Tonbridge Announces RSU Grants Under 2025 Share Incentive Scheme

Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( ($HK:2190) ) just unveiled an update. Zylox-Tonbridge Medical Technology Co.,...

15d ago

Zylox-Tonbridge Successfully Concludes 2025 EGM with All Resolutions Passed

An announcement from Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( ($HK:2190) ) is now available. Zylox-Tonbridge Medical...

15d ago

Zylox-Tonbridge to Discuss New Share Incentive Scheme at 2025 EGM

Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( ($HK:2190) ) has issued an update. Zylox-Tonbridge Medical Technology Co.,...

1M ago

Zylox-Tonbridge Announces Closure of H Share Register for 2025 EGM

Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( ($HK:2190) ) has provided an announcement. Zylox-Tonbridge Medical Technology Co.,...

1M ago

Zylox-Tonbridge Medical Technology Co., Ltd.: Strong Growth Potential Driven by VBP Programs and Overseas Expansion

Zylox-Tonbridge Medical Technology Co., Ltd. Class H, the Healthcare sector company, was revisited by a Wall Street analyst...

3M ago

Zylox-Tonbridge Proposes Share Incentive Scheme to Boost Competitiveness

Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( ($HK:2190) ) has issued an announcement. Zylox-Tonbridge Medical Technology Co.,...

3M ago

Zylox-Tonbridge Reports Strong Revenue Growth in H1 2025

The latest update is out from Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( ($HK:2190) ). Zylox-Tonbridge Medical...

3M ago

Zylox-Tonbridge Projects Strong Financial Growth in H1 2025

The latest announcement is out from Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( ($HK:2190) ). Zylox-Tonbridge Medical...

4M ago

Zylox-Tonbridge Schedules Board Meeting to Review Interim Results

Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( ($HK:2190) ) has issued an update. Zylox-Tonbridge Medical Technology Co.,...

4M ago

Zylox-Tonbridge Grants 250,000 Awards to Boost Long-term Growth

Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( ($HK:2190) ) just unveiled an announcement. Zylox-Tonbridge Medical Technology Co.,...

4M ago

2190 FAQ

What was Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s price range in the past 12 months?

Zylox-Tonbridge Medical Technology Co., Ltd. Class H lowest stock price was HK$10.56 and its highest was HK$26.60 in the past 12 months.

What is Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s market cap?

Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s market cap is HK$7.83B.

When is Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s upcoming earnings report date?

Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s upcoming earnings report date is Mar 19, 2026 which is in 131 days.

How were Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s earnings last quarter?

Zylox-Tonbridge Medical Technology Co., Ltd. Class H released its earnings results on Aug 20, 2025. The company reported HK$0.405 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.405.

Is Zylox-Tonbridge Medical Technology Co., Ltd. Class H overvalued?

According to Wall Street analysts Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Zylox-Tonbridge Medical Technology Co., Ltd. Class H pay dividends?

Zylox-Tonbridge Medical Technology Co., Ltd. Class H pays a Notavailable dividend of HK$0.109 which represents an annual dividend yield of 0.46%. See more information on Zylox-Tonbridge Medical Technology Co., Ltd. Class H dividends here

What is Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s EPS estimate?

Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Zylox-Tonbridge Medical Technology Co., Ltd. Class H have?

Zylox-Tonbridge Medical Technology Co., Ltd. Class H has 322,400,760 shares outstanding.

What happened to Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s price movement after its last earnings report?

Zylox-Tonbridge Medical Technology Co., Ltd. Class H reported an EPS of HK$0.405 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.183%.

Which hedge fund is a major shareholder of Zylox-Tonbridge Medical Technology Co., Ltd. Class H?

Currently, no hedge funds are holding shares in HK:2190

Company Description

Zylox-Tonbridge Medical Technology Co., Ltd. Class H

Zylox-Tonbridge Medical Technology Co., Ltd. Class H (2190) is a leading player in the medical technology sector, specializing in the research, development, manufacturing, and distribution of advanced medical devices and solutions. The company focuses on areas such as minimally invasive surgical instruments, diagnostic equipment, and healthcare IT solutions, aiming to enhance patient outcomes and streamline healthcare processes through innovative technology.

Zylox-Tonbridge Medical Technology Co., Ltd. Class H (2190) Earnings & Revenues

Historic Earnings Reports

2190 Stock 12 Month Forecast

Average Price Target

HK$28.62

▲(16.16% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"HK$6","12":"HK$12","18":"HK$18","24":"HK$24","30":"HK$30"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":29.9688646932,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$29.97</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.6229575962,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$28.62</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.9948676176,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$27.99</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,12,18,24,30],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2023","6":"Oct<br/>2023","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.3,24.736066514861538,25.172133029723078,25.608199544584615,26.044266059446155,26.480332574307692,26.916399089169232,27.35246560403077,27.78853211889231,28.224598633753846,28.660665148615386,29.096731663476923,29.53279817833846,{"y":29.9688646932,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.3,24.632535199707693,24.965070399415385,25.297605599123077,25.63014079883077,25.96267599853846,26.295211198246154,26.627746397953846,26.960281597661538,27.29281679736923,27.625351997076923,27.957887196784615,28.290422396492307,{"y":28.6229575962,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.3,24.58422058596923,24.86844117193846,25.152661757907694,25.436882343876924,25.721102929846154,26.005323515815384,26.289544101784617,26.573764687753847,26.857985273723077,27.142205859692307,27.42642644566154,27.71064703163077,{"y":27.9948676176,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.567,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.195,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.468,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.678,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.451,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7.795,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7.795,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.329,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.485,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.75,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.3,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >